⚡️ NIMITZ HEALTH NEWS FLASH ⚡️ 

“Budget Hearing: Department of Health and Human Services”

House Appropriations Labor, Health and Human Services, Education, and Related Agencies Subcommittee

April 16th, 2026 (recording linked here)

WITNESS

• The Honorable Robert F. Kennedy Jr.: Secretary, U.S. Department of Health and Human Services

QUICK SUMMARY

• The hearing focused on the HHS FY2027 budget, with debate over proposed funding cuts to major public health programs, including NIH, CDC, Medicaid, and behavioral health services.

• Significant attention was given to chronic disease policy, including prevention strategies, nutrition initiatives, and efforts to shift the healthcare system toward long-term health outcomes.

• Members raised concerns about agency operations, including workforce reductions, delayed disbursement of appropriated funds, and oversight of public health agencies and grant programs.

• Discussions highlighted healthcare system challenges such as rural hospital sustainability, maternal health disparities, drug pricing, and supply chain dependence on foreign pharmaceuticals.

• Contentious exchanges centered on vaccine policy, environmental health issues, reproductive health, and regulatory decisions affecting food safety, medical research, and public health guidance.

🐘 Republicans

• Emphasized shifting healthcare policy toward prevention, nutrition, and addressing chronic disease as core drivers of poor health outcomes.

• Supported efforts to reduce federal spending, eliminate waste and fraud, and restructure agencies to improve efficiency and accountability.

• Highlighted concerns about supply chain security, rural healthcare access, and regulatory reforms, while backing administration positions on issues like parental rights, abortion restrictions, and reduced reliance on foreign pharmaceuticals.

🫏 Democrats

• Criticized proposed budget cuts to public health programs, arguing they would harm access to care, increase costs, and weaken health infrastructure.

• Raised concerns about politicization of science, including vaccine policy, research funding decisions, and staffing changes at public health agencies.

• Focused on protecting funding for Medicaid, NIH, CDC, and social programs, while emphasizing health equity, maternal health, and the need for evidence-based policymaking.

MEMBER OPENING STATEMENTS

• Chair Aderholt (R-AL) welcomed the Secretary of Health and Human Services and emphasized the need to improve America’s healthcare system by focusing on better long-term health outcomes rather than increased spending alone. He argued that despite high federal healthcare expenditures, U.S. health outcomes lag behind other developed nations, particularly in life expectancy and rates of chronic disease. He praised Secretary Kennedy’s initiatives to address chronic illness, enforce conscience protections, and end certain medical practices involving minors, while also urging more attention to rural healthcare challenges. He concluded by expressing support for balanced investments in research and a willingness to work collaboratively on reforms.

• Ranking Member DeLauro (D-CT) thanked the Chair and Secretary, while commending efforts to regulate microplastics in drinking water and highlighting their health risks. She criticized the administration’s proposed budget cuts to health programs, arguing they would harm public health systems, increase costs, and reduce access to care. She further accused the administration of undermining scientific research, weakening public health agencies, and prioritizing political agendas over evidence-based policy. She concluded by firmly rejecting proposed funding cuts and asserting Congress’s authority over federal spending decisions.

WITNESS OPENING STATEMENTS

• Secretary Kennedy stated that the nation was at a turning point, arguing that children were the sickest generation in modern history due to failed policies and profit-driven systems. He described the administration’s efforts to reform healthcare, including lowering drug prices, increasing price transparency, reducing bureaucratic barriers, and addressing fraud and abuse. He highlighted initiatives to improve nutrition, expand partnerships, invest in rural healthcare, and accelerate treatment access, while emphasizing a shift toward prevention and public health. He concluded by calling for continued collaboration with Congress to implement lasting reforms aimed at reducing chronic disease and improving health outcomes nationwide.

QUESTION AND ANSWER SUMMARY

• Chair Aderholt (R-AL) questioned Secretary Kennedy about safety reporting requirements for the abortion drug mifepristone, but the Secretary declined to answer due to ongoing litigation.

  Chair Aderholt then raised concerns about rural healthcare reimbursement disparities, particularly the Medicare wage index, and urged further analysis to support potential legislative fixes. Secretary Kennedy acknowledged the issue, noting statutory constraints and expressing willingness to work with Congress on solutions.

• Ranking Member DeLauro (D-CT) pressed the Secretary on tobacco prevention, maternal health awareness, and the status of CDC staff on administrative leave, criticizing the continued sidelining of public health experts.

  Ranking Member DeLauro also raised concerns about FDA handling of a raw milk–related outbreak and questioned whether the Secretary’s personal views influenced agency actions. Secretary Kennedy defended the agency’s response, stating FDA pressured the company into a recall and emphasizing that raw milk regulation is largely handled by states.

• Rep. Letlow (R-LA) supported the administration’s “Make America Healthy Again” agenda and supported the nomination of Casey Means for Surgeon General. Secretary Kennedy praised Means as a leading advocate for metabolic health and prevention.

  Rep. Letlow also asked about maternal health initiatives, and Secretary Kennedy highlighted disparities and pointed to pilot programs that had reduced maternal mortality in participating hospitals.

• Rep. Hoyer (D-MD) questioned workforce reductions and rehiring at HHS, expressing concern that cuts were arbitrary and could harm agency effectiveness. Secretary Kennedy defended restructuring efforts, citing inefficiencies and duplication, and stated staffing levels were being restored with a focus on chronic disease.

  Rep. Hoyer also raised concerns about morale at CDC, while Secretary Kennedy said conditions had improved and emphasized plans to rebuild leadership.

• Rep. Ellzey (R-TX) focused on national security threats, including anthrax preparedness and cybersecurity risks from foreign-made medical devices. Secretary Kennedy affirmed that stockpiles and preparedness efforts were sufficient and highlighted initiatives to reduce reliance on Chinese supply chains and strengthen cybersecurity. The discussion also touched on broader biosecurity and medical countermeasure readiness.

• Rep. Pocan (D-WI) criticized lack of follow-up communication and raised concerns about delayed disbursement of congressionally appropriated funds. He questioned the administration’s stance on glyphosate, noting inconsistencies with prior statements, and highlighted concerns about animal testing practices tied to NIH-funded research. Secretary Kennedy acknowledged concerns about glyphosate but framed decisions within supply chain realities, and said he would review the animal research issue.

• Rep. Bice (R-OK) emphasized the importance of NIH funding and U.S. leadership in biomedical research, asking about budget priorities and competitiveness with China. Secretary Kennedy cited efforts to redirect funding toward chronic disease research and reduce inefficiencies, while also highlighting accelerated drug approvals and domestic investment in pharmaceutical production.

• Rep. Frankel (D-FL) criticized delays in releasing congressionally appropriated global vaccine funding and raised concerns about Medicaid funding gaps in Florida. She also opposed proposed cuts to Title X and fall prevention programs, arguing they would harm vulnerable populations. Secretary Kennedy responded that discussions with Florida were ongoing and acknowledged the scale of funding issues.

• Rep. Moolenaar (R-MI) asked about efforts to reshore pharmaceutical production and address reliance on China, as well as ethical concerns in foreign clinical trials. Secretary Kennedy highlighted investments in domestic manufacturing and increased inspections abroad.

  Rep. Moolenaar also discussed cybersecurity risks in healthcare and emerging alternatives to agricultural chemicals like glyphosate.

• Rep. Watson Coleman (D-NJ) challenged the Secretary’s claims about declining public health and questioned proposed cuts to LIHEAP and minority health programs. She emphasized health disparities affecting minority populations and the importance of targeted research funding. Secretary Kennedy acknowledged disparities but framed them in terms of broader social conditions and defended budget priorities.

• Rep. Clyde (R-GA) praised the administration’s healthcare policies and asked about protecting taxpayer funds and restricting abortion-related spending under Title X. Secretary Kennedy indicated forthcoming funding guidance and emphasized oversight efforts to prevent misuse of funds.

  Rep. Clyde also raised concerns about fraud in federal programs, and Secretary Kennedy described new measures to detect and prevent improper payments.

• Rep. Harder (D-CA) questioned the Secretary about mercury pollution policy changes under the administration, highlighting apparent inconsistencies with Kennedy’s past advocacy. Secretary Kennedy declined to comment on EPA actions, stating they were outside his jurisdiction, while reaffirming general concerns about mercury as a toxin. The exchange became contentious over accountability and policy alignment.

• Rep. Moore (R-WV) supported the administration’s public health agenda and asked about child care policy flexibility and family-based care. Secretary Kennedy expressed support for working on reforms and highlighted efforts to reduce foster care placements.

  Rep. Moore also asked about NIH policy changes on fetal tissue research, which Kennedy said had been finalized.

• Rep. Dean (D-PA) focused on vaccine policy, citing rising measles cases and declining vaccination rates, and questioned the replacement of vaccine advisory committee members. Secretary Kennedy defended his actions and disputed causation claims.

  Rep. Dean also raised concerns about cuts to mental health and substance abuse programs, while Secretary Kennedy argued funding was being reallocated rather than reduced overall.

• Rep. Harris (R-MD) supported reevaluating public health spending and questioned past vaccine policies and nutrition programs. He also raised concerns about Medicare Advantage overpayments and fraud in HHS programs. Secretary Kennedy described efforts to reduce fraud, including new oversight systems and enforcement actions targeting improper billing.

• Rep. Fleischmann (R-TN) asked about access to non-opioid pain treatments under Medicare and enforcement against illegal vaping products. Secretary Kennedy noted regulatory challenges with drug coverage and described enforcement actions against illicit vapes, as well as efforts to expand approved domestic alternatives.

• Ranking Member DeLauro reiterated concerns about delays in releasing appropriated funds and criticized proposed budget cuts to health programs, arguing they would harm affordability and access to care. She emphasized Congress’s intent to reject such cuts and maintain funding for key public health programs. Secretary Kennedy responded by defending fiscal discipline efforts and disputing claims of Medicaid cuts.

• Chair Aderholt concluded the hearing by highlighting bipartisan concerns, particularly around rural healthcare and abortion-related funding, and encouraged continued collaboration. He reiterated the importance of addressing rural disparities and thanked the Secretary for his testimony and engagement.